Back to results
US 2026/0308254 A1Published application
Cd3 binding molecules
AssigneeMerus N.V.
InventorPieter Fokko VAN LOO
Life of this patent
Estimating the term…
Abstract
The invention relates to heavy chain variable regions, binding domains and antibodies specific for human CD3, and CD3 binding proteins. The invention further relates to the use of a CD3 binding protein, preferably an antibody, of the invention in the treatment of cancer or autoimmune disease.
Claims34
-33. (canceled)
A method for treating a subject in need comprising administering the subject a therapeutically effective amount of an antigen-binding protein that binds human CD3 comprising an antibody variable domain comprising a heavy chain variable region and a light chain variable region wherein the heavy chain variable region comprises:
- a CDR1, CDR2 and CDR3 comprising the amino acid sequence
- CDR1:
- (SEQ ID NO:
- 42)
- SFGIS
- CDR2:
- (SEQ ID NO:
- 43)
- GFIPVLGTANYAQKFQG
- CDR3:
- (SEQ ID NO:
- 44)
- RGNWNPFDP;
- or
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 51)
- SKTFTIS;
- CDR2:
- (SEQ ID NO:
- 52)
- GIIPLFGTITYAQKFQG;
- CDR3:
- (SEQ ID NO:
- 53)
- RGNWNPFDP;
- or
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 60)
- SRTFTIS;
- CDR2:
- (SEQ ID NO:
- 61)
- SIIPIFGTITYAQKFQG;
- CDR3:
- (SEQ ID NO:
- 62)
- RGNWNPFDP;
- or
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 84)
- SKTLTIS;
- CDR2:
- (SEQ ID NO:
- 85)
- GIIPIFGSITYAQKFQD;
- CDR3:
- (SEQ ID NO:
- 86)
- RGNWNPFDP,
- or
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 68)
- GSGIS;
- CDR2:
- (SEQ ID NO:
- 69)
- GFIPFFGSANYAQKFRD;
- CDR3:
- (SEQ ID NO:
- 70)
- RGNWNPLDP;
- or
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 100)
- GSGIS;
- CDR2:
- (SEQ ID NO:
- 101)
- GFIPFFGSANYAQKFRD;
- CDR3:
- (SEQ ID NO:
- 102)
- RGNWNPFDP;
- or
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 199)
- RFWIG;
- CDR2:
- (SEQ ID NO:
- 200)
- IIYPGDSDTRYSPSFQG;
- CDR3:
- (SEQ ID NO:
- 201)
- HIRYFDWSEDYHYYLDV;
- or
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 208)
- RYWIG;
- CDR2:
- (SEQ ID NO:
- 209)
- IIYPGDSDTRYSPSFQG;
- CDR3:
- (SEQ ID NO:
- 210)
- NIRYFVWSEDYHYYMDV;
- or
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 117)
- SYALS;
- CDR2:
- (SEQ ID NO:
- 118)
- GISGSGRTTWYADSVKG;
- CDR3:
- (SEQ ID NO:
- 119)
- DGGYSYGPYWYFDL;
- or
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 125)
- SYALS;
- CDR2:
- (SEQ ID NO:
- 126)
- AISGSGRTTWYADSVKG;
- CDR3:
- (SEQ ID NO:
- 127)
- DGGYTYGPYWYFDL;
- or
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 142)
- DYTMH;
- CDR2:
- (SEQ ID NO:
- 143)
- DISWSSGSIGYADSVKG;
- CDR3:
- (SEQ ID NO:
- 144)
- DHRGYGDYEGGGFDY;
- or
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 150)
- DYTMH;
- CDR2:
- (SEQ ID NO:
- 151)
- DISWSSGSIGYADSVKG;
- CDR3:
- (SEQ ID NO:
- 152)
- DHRGYGDYEGGGFDH;
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 166)
- DYTMH;
- CDR2:
- (SEQ ID NO:
- 167)
- DISWSGGSIYYADSVKG;
- CDR3:
- (SEQ ID NO:
- 168)
- DHRGYGDYEGGGFDY;
- or
- comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 182)
- DYTMH;
- CDR2:
- (SEQ ID NO:
- 183)
- DISWSSGTTGYADSVKG;
- CDR3:
- (SEQ ID NO:
- 184)
- DHMGYGDYEGGGFDY;
- and wherein the light chain variable region comprises a CDR1, CDR2, and CDR3 region comprising the amino acid sequence:
- CDR1:
- (SEQ ID NO:
- 21)
- QSISSY;
- CDR2:
- (SEQ ID NO:
- 22)
- AAS;
- CDR3:
- (SEQ ID NO:
- 299)
- QQSYSTPPT.
204 more elements
Dependencies are inferred from the claim text.